The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD
This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Contemporary Clinical Trials Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865424001479 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545553673977856 |
|---|---|
| author | Jessica L. Maples-Keller Boadie W. Dunlop Barbara O. Rothbaum |
| author_facet | Jessica L. Maples-Keller Boadie W. Dunlop Barbara O. Rothbaum |
| author_sort | Jessica L. Maples-Keller |
| collection | DOAJ |
| description | This article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale for this novel treatment approach, including combining MDMA with a gold standard treatment, translational support for this treatment, strong dissemination potential, and strengths of providing massed exposure treatment. The specific methods of the open label pilot study are presented, followed by conclusions and future directions for this research. This study will enroll at least 15 adults with PTSD over the next 2 years in order to identify feasibility and lead to a manual describing how to combine MDMA with exposure therapy, tested in a randomized, placebo-controlled trial, with significant promise for dissemination and improving our ability to treat PTSD. Trial registration: ClinicalTrials.gov identifier: NCT05746572. |
| format | Article |
| id | doaj-art-fd0e1978ad2641759ef77f156a7b0e0f |
| institution | Kabale University |
| issn | 2451-8654 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Contemporary Clinical Trials Communications |
| spelling | doaj-art-fd0e1978ad2641759ef77f156a7b0e0f2025-01-12T05:25:29ZengElsevierContemporary Clinical Trials Communications2451-86542025-02-0143101400The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSDJessica L. Maples-Keller0Boadie W. Dunlop1Barbara O. Rothbaum2Corresponding author. 12 Executive Park Dr NE, Atlanta, GA, 30329, Georgia.; Emory University School of Medicine, Department of Psychiatry and Behavioral Sciences, GeorgiaEmory University School of Medicine, Department of Psychiatry and Behavioral Sciences, GeorgiaEmory University School of Medicine, Department of Psychiatry and Behavioral Sciences, GeorgiaThis article describes the rationale and the specific methods for an open label pilot trial of 100 mg MDMA in combination with massed exposure therapy for PTSD, a treatment which involves daily exposure therapy sessions for two weeks which has found to be effective. We review the need for novel PTSD treatments and the existing research on MDMA-assisted therapy, and then describe the rationale for this novel treatment approach, including combining MDMA with a gold standard treatment, translational support for this treatment, strong dissemination potential, and strengths of providing massed exposure treatment. The specific methods of the open label pilot study are presented, followed by conclusions and future directions for this research. This study will enroll at least 15 adults with PTSD over the next 2 years in order to identify feasibility and lead to a manual describing how to combine MDMA with exposure therapy, tested in a randomized, placebo-controlled trial, with significant promise for dissemination and improving our ability to treat PTSD. Trial registration: ClinicalTrials.gov identifier: NCT05746572.http://www.sciencedirect.com/science/article/pii/S2451865424001479MDMAPTSDClinical trialExposure therapyTreatmentPsychedelic |
| spellingShingle | Jessica L. Maples-Keller Boadie W. Dunlop Barbara O. Rothbaum The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD Contemporary Clinical Trials Communications MDMA PTSD Clinical trial Exposure therapy Treatment Psychedelic |
| title | The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD |
| title_full | The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD |
| title_fullStr | The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD |
| title_full_unstemmed | The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD |
| title_short | The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD |
| title_sort | metemp protocol massed exposure therapy enhanced with mdma for ptsd |
| topic | MDMA PTSD Clinical trial Exposure therapy Treatment Psychedelic |
| url | http://www.sciencedirect.com/science/article/pii/S2451865424001479 |
| work_keys_str_mv | AT jessicalmapleskeller themetempprotocolmassedexposuretherapyenhancedwithmdmaforptsd AT boadiewdunlop themetempprotocolmassedexposuretherapyenhancedwithmdmaforptsd AT barbaraorothbaum themetempprotocolmassedexposuretherapyenhancedwithmdmaforptsd AT jessicalmapleskeller metempprotocolmassedexposuretherapyenhancedwithmdmaforptsd AT boadiewdunlop metempprotocolmassedexposuretherapyenhancedwithmdmaforptsd AT barbaraorothbaum metempprotocolmassedexposuretherapyenhancedwithmdmaforptsd |